Fig 1: Serum expressions of miR-96-5p and BCL2L13 were measured in AMI-CAD patients and healthy controls. (a) The expression of miR-96-5p was dramatically decreased in serum samples from AMI-CAD patients. (b) The mRNA expression of BCL2L13 was dramatically increased in serum samples from AMI-CAD patients. (c) Western blot analysis and quantified results showed that the protein expression of BCL2L13 was dramatically increased in serum samples from AMI-CAD patients. (d) BCL2L13 expression was negatively correlated with miR-96-5p. **P < 0.01, AMI-CAD vs healthy. AMI-CAD, patients with acute myocardial infarction associated with coronary artery disease.
Fig 2: Effect of co-transfection with miR-96-5p and BCL2L13 on apoptosis-related factors. Western blotting results.
Fig 3: Expressions of miR-96-5p and BCL2L13 were measured after hypoxia treatment in H9c2 cells. (a) The expression of miR-96-5p was dramatically decreased after hypoxia treatment. (b) The mRNA expression of BCL2L13 was dramatically increased after hypoxia treatment. **P < 0.01, hypoxia vs normoxia.
Fig 4: BCL2L13 is a direct target of miR-96-5p. (a) The predictive binding sequences of miR-96-5p in the 3’-UTR of BCL2L13. (b) The correlation between miR-96-5p and BCL2L13 expression in hypoxia-treated H9c2 cells was evaluated. (c) Luciferase reporter assay. (d) RNA pull-down assay.
Supplier Page from Abcam for Anti-Bcl2-L-13 antibody [EP10625]